A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumoursAlastair Greystoke, William P. Steward, Sarah P. Blagden et al.|Annals of Oncology|2006Cited by 24
Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignanciesSimon Pacey, Johann S. de Bono, Ruth Plummer et al.|Journal of Clinical Oncology|2005Cited by 22
A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.Adam Sharp, Hendrik‐Tobias Arkenau, Anja Williams et al.|Journal of Clinical Oncology|2022Cited by 12
PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCLAdam Sharp, Hendrick-Tobias Arkenau, A. Williams et al.|HemaSphere|2022Cited by 5
777 Initial clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignanciesSarah Whelan, Janine Powers, Christopher Karim et al.|Regular and Young Investigator Award Abstracts|2022Cited by 2